Date:11/4/2009

- (40,444) Increase (decrease) in deferred revenue (2,722) (11,972) Increase (decrease) in other liabilities (2,823) 2,474 ------ ----- Net cash used in operating activities $(90,453) $(115,065) Cash flows from investing activities: Purchases of investments (298,054) (411,417) Sales of investments 11,923 28,590 Maturities of investments 266,202 506,348 Purchases of property and equipment (10,763) (15,064) Transaction costs from Novartis pulmonary asset sale (4,440) - Investment in Pearl Therapeutics Inc. - (4,236) --- ------ Net cash (used in) provided by investing activities $(35,132) $104,221 Cash flows from financing activities: Payments of loan and capital lease obligations (935) (1,910) Proceeds from issuances of common stock 3,821 477 ----- --- Net cash provided by (used in) financing activities $2,886 $(1,433) ------ ------- Effect of exchange rates on cash and cash equivalents (108) (303) ---- ---- Net decrease in cash and cash equivalents $(122,807) $(12,580) Cash and cash equivalents at beginning of period 155,584 76,293
'/>"/>

SOURCE Nektar Therapeutics Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related biology technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics to Host Conference Call to Discuss Todays Announcement of a New Partnership for NKTR-118 and NKTR-119
3. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
4. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
5. Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
6. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
7. Nektar Therapeutics Reports First Quarter 2009 Financial Results
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
9. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
10. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
11. Nektar Announces Retirement of Irwin Lerner from Board of Directors